Table 6.
Autoantibody prevalence amongst study participants.
| Autoantibody | Negative all | Females | Males | Positive all | Females | Males | Borderline all | Females | Males |
|---|---|---|---|---|---|---|---|---|---|
| Anti-nuclear autoantibodies (n = 1850; 850 females and 996 males) | 865 (47%) | 334 (40%) | 518 (52%) | 316 (17%) | 172 (20%) | 144 (14%) | 669 (36%) | 334 (39%) | 334 (34%) |
| Extractable nuclear antigen autoantibodies (n = 979; 501 females and 477 males) | 938 (96%) | 477 (95%) | 460 (96%) | 27 (3%) | 17 (3%) | 10 (2%) | 14 (1%) | 7 (1%) | 7 (1%) |
| Anti-neutrophil cytoplasmic autoantibodies (n = 1843; 844 females and 995 males) | 1406 (76%) | 620 (73%) | 782 (79%) | 145 (8%) | 88 (10%) | 57 (6%) | 292 (16%) | 136 (16%) | 156 (16%) |
| Anti-cardiolipin immunoglobulin G autoantibodies (n = 1830; 840 females and 986 males) | 1607 (88%) | 742 (88%) | 862 (87%) | 223 (12%) | 98 (12%) | 124 (13%) | — | — | — |
| Rheumatoid factor autoantibodies (n = 1660; 767 females and 899 males) | 1641 (99%) | 745 (71%) | 893 (78%) | 19 (1%) | 12 (1%) | 6 (1%) | — | — | — |
| Tissue transglutaminase autoantibodies (n = 1850; 850 females and 996 males) | 1731 (94%) | 801 (70%) | 926 (74%) | 119 (6%) | 49 (4%) | 70 (6%) | — | — | — |
| Thyroid peroxidase autoantibodies (n = 1848; 850 females and 994 males) | 1688 (91%) | 752 (66%) | 933 (75%) | 160 (9%) | 98 (9%) | 61 (5%) | — | — | — |
| Anti-cyclic citrullinated peptide autoantibodies (n = 188; 93 females and 95 males) | 180 (96%) | 90 (8%) | 90 (7%) | 8 (4%) | 3 (3%) | 5 (5%) | — | — | — |
Data is presented as frequencies with proportions included in brackets.